Aeterna Zentaris Inc. (AEZS)
Symbol Info
Listed Symbol AEZS
Name Aeterna Zentaris Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $
Price Info
21 Day Moving Average $1.8954
21 Day EMA $1.856170
50 Day Moving Average $2.1857
50 Day EMA $2.156570
200 Day EMA $2.743480
200 Day Moving Average 3.237120
52 Week High $5.57
52 Week Low $1.27
52 Week Change $-26.436800
Alpha -0.033884
Beta 1.0629
Standard Deviation 0.320690
R2 0.013024
Periods 60
Share Information
10 Day Average Volume 204,070
20 Day Average Volume 170,466
30 Day Average Volume 132,491
50 Day Average Volume 111,535
Outstanding Shares 16,440,760
Float Shares 16,440,760
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 48
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 27,870
Institute Holdings Percent 8.100000
Institute Sold Previous 3 Months 454,900
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $-0.51
7 Day Percent Change -28.49%
21 Day Price Change $-0.96
21 Day Percent Change -42.86%
30 Day Price Change $-0.8395
30 Day Percent Change -39.61%
Month To Date Price Change $-0.96
Month To Date Percent -42.86%
90 Day Price Change $-1.42
90 Day Percent Change -52.59%
Quarter To Date $-1.67
Quarter To Date Percent -56.61%
180 Day Price Change $-2.93
180 Day Percent Change -69.60%
200 Day Price Change $-2.5
200 Day Percent Change -66.14%
Year To Date $-1.66
Year To Date Percent -56.46%
Profile
Description AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline.
Details
Issue Type CS
Market Cap $21,044,173
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 16,629,290
CEO Michael Ward
Employees 22
Last Audit UQ
Classification
CIK 0001113423
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 315 Sigma Drive
Suite 302D
Summerville, SC 29486
Website https://www.zentaris.com
Facisimile
Telephone +1 843 900-3201
Email IR@aezsinc.com
Key Ratios
Profitability
EBIT Margin -497.8
EBITDA Margin -490.9
Pre-Tax Profit Margin -33,870.6
Profit Margin Cont -
Gross Margin 12.20
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $0.2822
Revenue 3 Years $134.83
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $20,813,699
Price To Sales 4.535215
Price To Free Cash -3
PE High Last 5 Years -
Price To Book 34.1
Price To Cash Flow 9.9
PE Low Last 5 Years -
Price To Tangible Book -2.7
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 1.7
Leverage Ratio 37.3
Quick Ratio 1.4
Long Term Debt To Capital -
Assets
Receivables Turnover 10.1
Invoice Turnover 2.00
Assets Turnover 0.20
Management Effectiveness
Return Assets -47.09
Return On Equity -380.26
Return On Capital -281.19
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AEZS
Aeterna Ze..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.